Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen Hopes For Broad T-VEC Label, But Is Prepared To Discuss Narrower Approach

This article was originally published in The Pink Sheet Daily

Executive Summary

The big biotech reported a strong financial quarter while updating on several R&D and business catalysts, including the potential indications for its PCSK9 inhibitor.


Related Content

PCSK9 Mechanism Lends Confidence Ahead Of Outcomes Data
“Now Is The Time” For Japan, Amgen Says; Inks Strategic Alliance With Astellas


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts